scholarly article | Q13442814 |
P2093 | author name string | Averell Gnatt | |
Antonino Passaniti | |||
Alexander D MacKerell | |||
Moran Choe | |||
Jessica Bennett | |||
David R D'Souza | |||
Karen F Underwood | |||
Bahru Habtemariam | |||
Adam D Pierce | |||
Maria Mochin-Peters | |||
Sravya Kommineni | |||
P2860 | cites work | Structural basis for the heterodimeric interaction between the acute leukaemia-associated transcription factors AML1 and CBFbeta | Q22254263 |
The leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp | Q27630870 | ||
VMD: visual molecular dynamics | Q27860554 | ||
Cbfbeta interacts with Runx2 and has a critical role in bone development | Q28586662 | ||
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition | Q29400901 | ||
Solvent-accessible surfaces of proteins and nucleic acids | Q29614464 | ||
A functional analysis of the CREB signaling pathway using HaloCHIP-chip and high throughput reporter assays | Q30876900 | ||
Functions of 1alpha,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer | Q31943367 | ||
Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down | Q33513312 | ||
The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control | Q33670411 | ||
Vitamin D: metabolism | Q33888727 | ||
Development of a sensitive multi-well colorimetric assay for active NFkappaB | Q34233830 | ||
Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity | Q34739582 | ||
Vitamin D: marker or mechanism of action? | Q34779961 | ||
Nuclear microenvironments support assembly and organization of the transcriptional regulatory machinery for cell proliferation and differentiation | Q35638442 | ||
Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression | Q35779750 | ||
Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery | Q36062585 | ||
Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation | Q36329898 | ||
Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene | Q36550226 | ||
Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. | Q36682092 | ||
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics | Q36919979 | ||
Cyclin D1-cdk4 induce runx2 ubiquitination and degradation | Q37113937 | ||
Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway | Q37258582 | ||
HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching | Q38347789 | ||
Epidermal growth factor and bone morphogenetic proteins upregulate osteoblast proliferation and osteoblastic markers and inhibit bone nodule formation | Q39680824 | ||
The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation | Q40144929 | ||
Mitotic control of RUNX2 phosphorylation by both CDK1/cyclin B kinase and PP1/PP2A phosphatase in osteoblastic cells | Q40195895 | ||
Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation | Q40331133 | ||
Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells | Q40374373 | ||
Identification of novel extracellular signal-regulated kinase docking domain inhibitors. | Q40401482 | ||
Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway | Q40526648 | ||
Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. | Q40539678 | ||
Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling | Q40540364 | ||
Regulation of TGFbeta1-mediated growth inhibition and apoptosis by RUNX2 isoforms in endothelial cells | Q40563055 | ||
Indispensable role of the transcription factor PEBP2/CBF in angiogenic activity of a murine endothelial cell MSS31. | Q40904563 | ||
Electrophoretic mobility shift assay (EMSA) for detecting protein-nucleic acid interactions | Q41902384 | ||
Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. | Q42826927 | ||
Receptor-DNA interactions: EMSA and footprinting | Q44828841 | ||
CDK11p58 represses vitamin D receptor-mediated transcriptional activation through promoting its ubiquitin-proteasome degradation. | Q45962907 | ||
Prediagnostic serum vitamin D and breast cancer | Q46780572 | ||
Energetic and functional contribution of residues in the core binding factor beta (CBFbeta ) subunit to heterodimerization with CBFalpha. | Q52165310 | ||
An evaluation of the biologic activity and vitamin D receptor binding affinity of the photoisomers of vitamin D3 and previtamin D3 | Q56087774 | ||
Vitamin D and Reduced Risk of Breast Cancer: A Population-Based Case-Control Study | Q58231837 | ||
P433 | issue | 4 | |
P921 | main subject | cholecalciferol | Q139347 |
P304 | page(s) | 913-925 | |
P577 | publication date | 2012-04-01 | |
P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
P1476 | title | Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity | |
P478 | volume | 27 |
Q38312698 | A quantitative assay to study protein:DNA interactions, discover transcriptional regulators of gene expression, and identify novel anti-tumor agents |
Q42378493 | Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity |
Q43753628 | Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study |
Q40014606 | Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells |
Q36329328 | Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer |
Q64902344 | RUNX family: Oncogenes or tumor suppressors (Review). |
Q36413997 | RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells |
Q33697210 | RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion |
Q36947310 | The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells |
Q45316819 | Transcriptional regulation by RUNX2 |
Q38712047 | Vitamin D Impacts the Expression of Runx2 Target Genes and Modulates Inflammation, Oxidative Stress and Membrane Vesicle Biogenesis Gene Networks in 143B Osteosarcoma Cells |